Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (725)	5/29/2007 4:00:37 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Yes, but we may have to wait until management's discussion tomorrow of the 1stQ results, since revenues & earnings were down more than 50%.<g> biz.yahoo.com OTOH, INGN seems to have found support at the $4 level.<g> bigcharts.marketwatch.com RAGL Bernard

To: zeta1961 who wrote (725)	5/29/2007 7:29:21 PM
From: Jibacoa	Respond to of 802

Will see how much help the stock will get from the ASCO & ASGT meetings. biz.yahoo.com Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings Tuesday May 29, 8:30 am ET Updated Phase 2 Tumor Response and Survival Data with ADVEXIN(R), INGN 225 and INGN 241 to Be Presented at ASCO and ASGT AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN - News) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle. "We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade." ASCO * Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute. * Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc. ASGT * Role of the Immune System in Replicating Adenovirus Using a Permissive Immune Competent Syrian Hamster Model, William Wold, Ph.D., St. Louis University School of Medicine: Presentation on Thurs.,May 31, from 9:30 - 11:30 a.m. at Washington State Convention Center during symposium titled "Cancer: Hot Topics in Cancer Gene Therapy" * MDA-7 (INGN-241) Kills Chemoresistant Cancer Cells and Restores Chemosensitivity to Cisplatin, Abstract #197: Presentation during "Cancer: Apoptosis and Suicide" poster session on Thurs., May 31, from 5:00 - 8:00 p.m. at Washington State Convention Center by Rajagopal Ramesh, Ph.D., M. D. Anderson Cancer Center * Effect of Pre-existing Anti-Adenovirus Immunity and Anti-Tumor Immunity on the Efficacy of Adenovirus Vectors in Immunocompetent Syrian Hamster Model, Abstract #668: Presentation during "Immune Responses to Adenoviral Vectors" poster session on Fri, June 1, from 5:15- 8:15 p.m. in Hall 4AB at Washington State Convention Center by Debanjan Dhar, St. Louis University School of Medicine * Anticancer Activity of Oncolytic Adenovirus Vector Armed with IFN-alpha and ADP is Enhanced by Pharmacologically-Controlled Expression of TRAIL, Abstract #588: Presentation during "Cancer Immunotherapy II" poster session on Fri., June 1, 2007 from 5:15 - 8:15 p.m. in Hall 4AB at Washington State Convention Center by Elena V. Shashkova, VirRx, Inc. * Clinical Experience with the mda-7/IL-24 Tumor Suppressor, Abstract # 380: Presentation during "Tumor Suppressor and Targeted Gene Therapy" poster session and oral presentation on Friday, June 1, 2007 at 8:45 a.m. at the Washington State Convention Center by Sunil Chada, Ph.D., Introgen Therapeutics, Inc. Snip The stock did OK today, but it isn't doing as well AHs.<g> bigcharts.marketwatch.com Bernard

To: zeta1961 who wrote (725)	6/6/2007 11:22:15 PM
From: Jibacoa	Respond to of 802

Some posting on Seeking Alpha about Benda: Benda Pharma Offers First Gene Therapy For Cancer In The World Posted on Jun 6th, 2007 with stocks: BPMA.OB chinabiotodaynewlogo ChinaBio Today submits: On May 21, Benda Pharma (BPMA.OB) reported revenue of $3 million for Q1 of 2007, a decrease of 17% from the year-earlier period. Benda blamed the decrease on a temporary closing of its bulk chemical plant, a closing undertaken at the behest of the Chinese government, which mandated a cleanup of the wastewater of the plant. The plant is scheduled to be back online in August of this year. Net income dropped to $0.4 million for the quarter, a decline of 51%. Besides the plant closing, Benda said it encountered additional expenses associated with being a public company. Benda has 96.3 million shares outstanding and, at its current price of $1.70 per share, it has a market capitalization of $164 million. Benda is involved in making western and Traditional Chinese Medications, and it manufactures active pharmaceutical ingredients. In April of 2007, Benda bought a 57.57% ownership in Shenzhen SiBiona, which produces the cancer drug Gendicine, the first gene therapy medication for cancer available anywhere in the world. In 2004, Gendicine was approved by Chinese officials for use against head and neck cancer, which is also known as squamous cell cancer. The drug is injected once per week for eight weeks. In the Chinese trials, it achieved a complete remission in 64% of the cases and a partial remission in 32% of the patients. Gendicine was originally priced at $362 per injection. To buy the stake in SiBiono, Benda paid $7.7 million and gave SiBiono 2.1 million shares of Benda stock in return for financial consulting services. Benda also guaranteed that its shares would be worth $3.60 per share within three months after the expiration of the 12-month restriction on selling the shares. Benda operates three plants in the Hubei Province of China: Benda Ebei, which produces conventional medicines and Traditional Chinese Medicines; Jiangling Benda, which produces active pharmaceutical; and Yidu Benda, which produces bulk chemicals.